Crescent Biopharma (CBIO) Operating Income (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Operating Income of -$26.4 million for Q2 2026, down 25.36% year-over-year from -$35.3 million in Q2 2025, and down 6.61% quarter-over-quarter from -$24.7 million in Q1 2026.
Crescent Biopharma (CBIO) Operating Income (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Operating Income for 14 consecutive years, with -$26.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Operating Income fell 25.36% year-over-year to -$26.4 million; the TTM figure through Jun 2026 stood at -$168.5 million (down 164.56% YoY), while the FY2025 annual figure was -$152.6 million, down 281.2% from the prior year.
- Operating Income retreated to -$26.4 million in Q2 2026 per CBIO's latest filing, from -$24.7 million in the prior quarter.
- Across five years, Operating Income topped out at -$8.8 million in Q3 2022 and bottomed at -$91.5 million in Q4 2025.
- Historically, Operating Income has averaged -$18.9 million across 5 years, with a median of -$12.3 million in 2022.
- Annual changes were most pronounced in 2022 — Operating Income jumped 49.43% — and 2025, when it slumped 432.21%.
- Crescent Biopharma's Operating Income stood at -$10.6 million in 2022, then advanced by 9.71% to -$9.6 million in 2023, then slumped by 79.24% to -$17.2 million in 2024, then plunged by 432.21% to -$91.5 million in 2025, then surged by 71.18% to -$26.4 million in 2026.
- Business Quant data shows CBIO's Operating Income at -$26.4 million in Q2 2026, -$24.7 million in Q1 2026, and -$91.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - | -26.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.36 Mn |
| Mar 31, 2026 | -24.73 Mn |
| Dec 31, 2025 | -91.49 Mn |
| Sep 30, 2025 | -25.89 Mn |
| Jun 30, 2025 | -21.03 Mn |
| Mar 31, 2025 | -14.22 Mn |
| Dec 31, 2024 | -17.19 Mn |
| Sep 30, 2024 | -11.23 Mn |
| Jun 30, 2024 | -10.36 Mn |
| Mar 31, 2024 | -11.12 Mn |
| Dec 31, 2023 | -9.59 Mn |
| Sep 30, 2023 | -9.81 Mn |
| Jun 30, 2023 | -8.93 Mn |
| Mar 31, 2023 | -10.94 Mn |
| Dec 31, 2022 | -10.62 Mn |
| Sep 30, 2022 | -8.77 Mn |
| Jun 30, 2022 | -13.35 Mn |
| Mar 31, 2022 | -14.66 Mn |
| Dec 31, 2021 | -17.43 Mn |
| Sep 30, 2021 | -17.34 Mn |